Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFINITE: Implementation of ICG Fluorescence for Sentinel Lymph Node Biopsy in Breast Cancer
NCT07146295Recruiting
- Start
- Apr 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of indocyanine green in breast cancer (3 arms). Primary endpoint: Adoption of ICG for sentinel lymph node biopsy (SLNB). Started Apr 2025; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07146295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146295.